Table 1 Patient characteristics.

From: Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy

Patients

T stage

N stage

cStage

Tissue type*

EGFR

ALK

PD-L1

   

(UICC 8th)

   

IHC

Patient 1

2b

2

3 A

LUAD

Wild

Wild

10-24%

Patient 2

2a

2

3 A

LUAD

Exon19 del

N.D.

<1%

Patient 3

2a

2

3 A

LUAD

Wild

N.D.

N.D.

Patient 7

2a

2

3 A

LUAD

Wild

N.D.

1-4%

Patient 8

2a

2

3 A

LUAD

Wild

N.D.

1-4%

Patient 11

1c

2

3 A

LUAD

Exon19 del

Wild

N.D.

Patient 12

3

1

3 A

LUAD

Wild

Wild

25-49%

Resection alone

1c

1

2B

LUAD

Wild

Wild

N.D.

  1. *LUAD Lung adenocarcinoma.
Back to article page